Recent news on Gemifloxacin

Oscient Pharmaceuticals to Participate in the Sixth Annual JMP ...  -  May 15, 2007
Genetic Engineering News (press release),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

Tablets for Five-Day Treatment of Community-Acquired Pneumonia  -  May 9, 2007
Pharmaceutical Processing,The FDA has approved Oscient Pharmaceuticals' FACTIVE® (gemifloxacin mesylate) tablets for the five-day treatment of community-acquired pneumonia of mild to

FDA Approves Oscient Pharmaceuticals' FACTIVE Tablets for Five-Day ...  -  May 3, 2007
Compliance Home,...(May 02, 2007)-- The US Food and Drug Administration (FDA) has approved Oscient Pharmaceuticals' (Nasdaq: OSCI) FACTIVE (gemifloxacin mesylate) tablets for

Oscient Pharmaceuticals Announces Successful Convertible Debt ...  -  26 Apr 2007
Business Wire (press release),FACTIVE ® (gemifloxacin mesylate) tablets is an antibiotic FDA-approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

Oscient Pharmaceuticals Provides Preliminary Revenue Results for ...  -  Apr 11, 2007
PharmaLive.com (press release),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

ANA380 Exhibits Activity In Vitro Against Multiple Clinically ...  -  Apr 16, 2007
Drug Newswire (press release),LGLS seeks to continue developing global brand products, such as Factive(R) (gemifloxacin), and expanding its market presence in the world with focus in

New Treatment Guidelines for Community-Acquired Pneumonia ...  -  Feb 22, 2007
PharmaLive.com (press release),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

News from Oscient Pharmaceuticals highlights the most recent ...  -  Jan 11, 2007
Therapeutics Daily (subscription) (press release),In a poster focused on short-course gemifloxacin therapy in CAP patients with certain risk factors, researchers analyzed data from Oscient's Phase III trial

Oscient Pharmaceuticals and Menarini Group Enter into European ...  -  Jan 5, 2007
PipelineReview.com (press release),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

Oscient shares soar on Factive licensing pact amendment  -  Dec 29, 2006
ReutersFactive tablets, also known as gemifloxacin mesylate, are used to treat acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia

Oscient, LG Life Sci. expand Factive pact  -  Dec 29, 2006
United Press InternationalSpecifically, the company said the amended license and option contract on Oscient's antibiotic Factive (gemifloxacin mesylate) tablets, adds several

Oscient Pharmaceuticals to Present at 25th Annual JPMorgan ...  -  Dec 19, 2006
Genetic Engineering News (press release),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

Officials from Oscient Pharmaceuticals provide details of new ...  -  Dec 7, 2006
Therapeutics Daily (subscription) (press release),In a poster focused on short-course gemifloxacin therapy in CAP patients with certain risk factors, researchers analyzed data from Oscient's Phase III trial

Oscient Pharmaceuticals Reports Financial Results for Third ...  09 Nov 2006
...quarter of 2006 included $4.3 million from ANTARA(R) (fenofibrate) capsules, $4.0 million in revenues related to FACTIVE(R) (gemifloxacin mesylate) tablets ... -Genetic Engineering News (press release), Five-Day Therapy Course With Gemifloxacin Effective Against ...  Oct 16, 2006
TORONTO, CANADA -- October 16, 2006 -- Five days of treatment with gemifloxacin is as effective as the standard 7-day treatment in treating at-risk patients ... -DG News FACTIVE(R) Tablets Subject of Five Presentations at Third ...  Oct 9, 2006
NIAGARA-ON-THE-LAKE, ONTARIO, Canada--(BUSINESS WIRE)--FACTIVE(R) (gemifloxacin mesylate) tablets, Oscient Pharmaceuticals Corporation’s (Nasdaq: OSCI) lead ... -Business Wire (press release), Data on Factive Tablets Short-Course Therapy in Patients with Co ...  Oct 13, 2006
Meeting of the Infectious Diseases Society of America (IDSA) examined the outcome of short-course treatment with FACTIVE(R) (gemifloxacin mesylate) tablets ... -PharmaLive.com (press release), FACTIVE(R) Tablets Subject of Five Presentations at Third ...  Oct 9, 2006
FACTIVE(R) (gemifloxacin mesylate) tablets, Oscient Pharmaceuticals Corporation's (Nasdaq: OSCI) lead antibiotic product, is the subject of five poster ... -Genetic Engineering News (press release), Factive Tablets Subject of Five Presentations at Third ...  Oct 9, 2006
NIAGARA-ON-THE-LAKE, ONTARIO, Canada--(BUSINESS WIRE)--Oct 9, 2006 - FACTIVE(R) (gemifloxacin mesylate) tablets, Oscient Pharmaceuticals Corporation's (Nasdaq ... -PharmaLive.com (press release), Replidyne's Glenn Tillotson Elected a Fellow of the American ...  Nov 6, 2006
Therapeutics. Dr. Tillotson's experience and expertise with Oscient's Factive (gemifloxacin) made him an ideal fit for Replidyne. Dr ... -Earthtimes.org Replidyne's Glenn Tillotson Elected a Fellow of the American ...  Nov 6, 2006
Therapeutics. Dr. Tillotson 's experience and expertise with Oscient's Factive (gemifloxacin) made him an ideal fit for Replidyne. Dr ... -Genetic Engineering News (press release), Oscient Pharmaceuticals to Present at Rodman & Renshaw 8 th Annual ...  Oct 30, 2006
...details on the acquisition of ANTARA(R) 130 mg (fenofibrate) capsules and preparation for the third winter season for FACTIVE(R) (gemifloxacin mesylate) tablets ... -Business Wire (press release), Market Report -- In Play (OSCI)  Oct 13, 2006
In a poster focused on short-course gemifloxacin therapy in CAP patients with certain risk factors, researchers analyzed data from Oscient's Phase III trial ... -MSN Money Webcast Alert: Oscient Pharmaceuticals Announces Date for Release ...  Oct 25, 2006
The Company markets two products: FACTIVE ® (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... -Business Wire (press release), Oscient Pharmaceuticals Provides Preliminary Revenue Results for ...  Oct 11, 2006
...$4 million from ANTARA(R) 130 mg (fenofibrate) capsules and approximately $4 million in revenues related to FACTIVE(R)(gemifloxacin mesylate) tablets. ... -Business Wire (press release), Market Report -- In Play (OSCI)  Oct 11, 2006
Approximately $4 mln came from Antara 130 mg (fenofibrate) capsules and approximately $4 mln in revenues related to Factive (gemifloxacin mesylate) tablets. ... -MSN Money Oscient Pharmaceuticals Receives Approvable Letter from FDA for ...  Sep 22, 2006
...seeking approval for the five-day treatment of community-acquired pneumonia (CAP) of mild to moderate severity with FACTIVE(R) (gemifloxacin mesylate) tablets. ... -PharmaLive.com

Oscient Pharmaceuticals Announces Results of FDA Advisory ...  Sep 13, 2006
...on topics related to the Company's pending supplemental New Drug Application (sNDA) seeking approval for the use of FACTIVE(R) (gemifloxacin mesylate) tablets ... -Genetic Engineering News

Antibiotic for sinuses is questioned  Sep 11, 2006
...minor infections, the incident of serious rashes has Food and Drug Administration officials concerned about the safety of the drug, Factive or gemifloxacin. ... -Seattle Post Intelligencer

DAILY CHECK-UP  Sep 19, 2006
11-2 vote. Studies have found serious skin reactions associated with use of the drug, also known as gemifloxacin. The FDA approved ... -Kentucky.com

Oscient Pharmaceuticals Stock Trading Halted Today; FDA Advisory ...  Sep 12, 2006
Administration (FDA) meets today to review and discuss the Company's supplemental New Drug Application (sNDA) for FACTIVE(R) (gemifloxacin mesylate) tablets ... -Genetic Engineering News

Antibiotic For Sinuses Is Questioned  Sep 11, 2006
...released Monday. Food and Drug Administration officials concerned about the safety of the drug, Factive or gemifloxacin. The regulatory ... -CBS 3

FDA concerned about new use of Oscient antibiotic  Sep 11, 2006
The company said Factive, known generically as gemifloxacin, "represents an important additional therapeutic option for treatment of ABS (sinusitis ... -MarketWatch

FDA Panel Recommends Against Using Factive To Treat Sinus ...  Sep 13, 2006
Washington , DC (AHN) - A Food and Drug Administration advisory panel says the use of the antibiotic Factive (gemifloxacin) should not be expanded to treat ... -All Headline News

FDA Advisers Oppose Wider Label For Factive In Sinusitis  Sep 12, 2006
By Aaron Lorenzo. GAITHERSBURG, Md. - The FDA's Anti-Infective Drugs Advisory Committee voted against expanding the label for Factive (gemifloxacin) to include ... -BioWorld Online

Proposed antibiotic raises concerns in US  Sep 15, 2006
...minor infections, the incidence of serious rashes has Food and Drug Administration officials concerned about the safety of the drug, Factive or gemifloxacin. ... -Waterloo Record

Oscient Pharmaceuticals to Present at Thomas Weisel Healthcare ...  Aug 30, 2006
Company including details on the acquisition of ANTARA(R) 130 mg (fenofibrate) capsules and the recent sublicense of FACTIVE(R) (gemifloxacin mesylate) tablets ... -Business Wire

UPDATE: FDA Panel Rejects Expansion Of Oscient Antibiotic  Sep 12, 2006
Oscient officials agreed that Factive, known generically as gemifloxacin, carried a higher rate of rash but said it could be reduced with a shorter, five-day ... -Easy Bourse (Communiqués de presse)

Antibiotic fails to win panel‘s support  Sep 12, 2006
11-2 vote. Studies have found serious skin reactions associated with use of the drug, also known as gemifloxacin. In documents filed ... -Herald News Daily

Oscient Pharmaceuticals and Auxilium Pharmaceuticals Agree to ...  Sep 5, 2006
The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... -Business Wire

Oscient Pharmaceuticals Provides Financial Projections for Fiscal ...  -  Dec 8, 2006
Genetic Engineering News (press release),FACTIVE(R) (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and

Officials from Oscient Pharmaceuticals provide details of new ...  -  Dec 7, 2006
Therapeutics Daily (subscription) (press release),In a poster focused on short-course gemifloxacin therapy in CAP patients with certain risk factors, researchers analyzed data from Oscient's Phase III trial

Oscient completes buy of heart drug Antara  Aug 21, 2006
..."Combined with the continued success of our flagship antibiotic, Factive (gemifloxacin mesylate) tablets, Antara will further our growth as a commercial-stage ... -United Press International

Oscient Pharmaceuticals Hires Inder Kaul, MD, MPH as Vice ...  Aug 21, 2006
The Company is marketing FACTIVE(r) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... -PharmaLive.com

Oscient Pharmaceuticals Completes Acquisition of Cardiovascular ...  Aug 21, 2006
Combined with the continued success of our flagship antibiotic, FACTIVE(R) (gemifloxacin mesylate) tablets, ANTARA will further our growth as a commercial ... -PharmaLive.com

Oscient agrees to acquire Antara rights from Reliant ...  Aug 23, 2006
...of the $1 billion fenofibrate market and will be commercialized by Oscient's national sales force, which is marketing Factive (gemifloxacin mesylate) tablets ... -Therapeutics Daily (subscription)

Oscient Pharmaceuticals and Pfizer, SA de CV Announce Approval of ...  Aug 1, 2006
FACTIVE(R) (gemifloxacin mesylate) tablets, Oscient Pharmaceuticals Corporation's (Nasdaq: OSCI) lead antibiotic product, has been approved by the Ministry of ... -Genetic Engineering News

Oscient Pharmaceuticals and Abbott Canada Enter into ...  Aug 10, 2006
Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) has granted the commercialization rights to FACTIVE(R) (gemifloxacin mesylate) tablets in Canada to Abbott ... -Genetic Engineering News

Oscient Pharmaceuticals and Abbott Canada Enter into ...  Aug 10, 2006
WIRE)--Aug 10, 2006 - Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) has granted the commercialization rights to FACTIVE(R) (gemifloxacin mesylate) tablets ... -PharmaLive.com

Oscient, Abbott unit in pact for Factive  Aug 10, 2006
...tablets. Factive tablets, also known as gemifloxacin mesylate, is used to treat acute bacterial exacerbations of chronic bronchitis. ... -Reuters

Oscient Paying Reliant $78M For Cholesterol Drug In US  Jul 25, 2006
...about $35 million in revenue for Reliant over the past 12 months, will be marketed by Oscient's sales force along with Factive (gemifloxacin mesylate) tablets. ... -BioWorld Online

Oscient Pharmaceuticals Announces Meeting Date for FDA Advisory ...  Jun 28, 2006
...that the FDA's Anti-Infective Drugs Advisory Committee will review the supplemental New Drug Application (sNDA) for FACTIVE(R) (gemifloxacin mesylate) tablets ... -Business Wire

Factive To Get Committee Review Sept. 12 For Acute Bacterial ...  Jun 28, 2006
FDA’s Anti-Infective Drugs Advisory Committee will review Oscient’s sNDA for the antibiotic Factive (gemifloxacin) Sept. 12 ... -FDA Advisory Committee



Oscient Pharmaceuticals Reports Financial Results for First ...  May 9, 2006
In the first quarter of 2006, $9.2 million in revenue was generated from the Company's lead product, FACTIVE(R) (gemifloxacin mesylate) tablets, FDA-approved ... - Genetic Engineering News

Webcast Alert: Oscient Pharmaceuticals Announces Date for Release ...  Apr 20, 2006
The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of chronic ... - Genetic Engineering News

Completion of ANA380 Dosing in Phase II Clinical Trial Confirms ...  Apr 26, 2006
LGLS seeks to continue developing global brand products, such as Factive(R) (gemifloxacin), and expanding its market presence in the world with focus in Asia. ... - PharmaLive.com





Oscient Pharmaceuticals' FACTIVE Tablets Subject of Poster ...  Apr 4, 2006
Oscient Pharmaceuticals Corporation's (Nasdaq: OSCI) lead product, FACTIVE(R) (gemifloxacin mesylate) tablets, is the subject of two poster presentations at ... - International News Service

Oscient Pharmaceuticals' FACTIVE Tablets Subject of Poster ...  Apr 4, 2006
NICE, France--(BUSINESS WIRE)--April 4, 2006--Oscient Pharmaceuticals Corporation's (Nasdaq: OSCI) lead product, FACTIVE(R) (gemifloxacin mesylate) tablets, is ... - Business Wire

Oscient Pharmaceuticals Announces $35 Million Private Placement ...  Apr 6, 2006
The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of chronic ... - Genetic Engineering News

Sinovac Biotech Ltd., and LG Life Sciences, Ltd. Announce ...  Mar 12, 2006
LGLS seeks to continue developing global brand products, such as Factive(R) (gemifloxacin), and expanding its market presence in the world with focus in Asia. ... - PR Newswire



Oscient Pharmaceuticals to Present at Fifth Annual JMP Securities ...  Mar 2, 2006
...and CEO, Steven Rauscher, will provide an overview of the Company including details on the recent sublicense of FACTIVE(R) (gemifloxacin mesylate) tablets in ... - Genetic Engineering News,

Oscient Pharmaceuticals and Pfizer Enter Agreement for FACTIVE ...  Feb 7, 2006
Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) has sublicensed the commercialization rights to FACTIVE(R) (gemifloxacin mesylate) tablets in Mexico to ... - Genetic Engineering News,

Oscient Pharmaceuticals y Pfizer celebran acuerdo por las...  Feb 7, 2006
The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... - Nosis NyM,

Robust Viral Load Reduction Successfully Achieved in Phase II ...  Feb 14, 2006
LGLS seeks to continue developing global brand products, such as Factive(R) (gemifloxacin), and expanding its market presence in the world with focus in Asia. ... - PharmaLive.com,

Webcast Alert: Oscient Pharmaceuticals to Present at BIO CEO & ...  09 Feb 2006
...and CEO, Steven Rauscher, will provide an overview of the Company including details on the recent sublicense of FACTIVE(R) (gemifloxacin mesylate) tablets in ... - Genetic Engineering News

Oscient Pharmaceuticals Provides Preliminary Revenues for Fourth ...  Jan 9, 2006
...quarter revenues of approximately $9.2 million, with approximately $8 million in revenue from its lead product, FACTIVE(R) (gemifloxacin mesylate) tablets, and ... - Genetic Engineering News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional